Bifidobacterium longum subsp. infantis CECT7210 ( B. infantis IM-1 ® ) Displays In Vitro Activity against Some Intestinal Pathogens

• Published in: Nutrients 2020-10, Vol.12 (11), p.3259
• Main Authors: Ruiz, Lorena, Flórez, Ana Belén, Sánchez, Borja, Moreno-Muñoz, José Antonio, Rodriguez-Palmero, Maria, Jiménez, Jesús, Gavilán, Clara G de Los Reyes, Gueimonde, Miguel, Ruas-Madiedo, Patricia, Margolles, Abelardo
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Bifidobacterium longum; Bifidobacterium longum subspecies infantis; Clostridioides difficile - drug effects; Coculture Techniques; Complex Mixtures; Cronobacter sakazakii - drug effects; enteropathogens; Escherichia coli - drug effects; Female; Gastrointestinal Tract - microbiology; HT29 Cells; Humans; Infant; Infant, Newborn; Intestines - microbiology; Listeria monocytogenes - drug effects; Male; Oligosaccharides - pharmacology; prebiotics; Prebiotics - microbiology; probiotics; Probiotics - pharmacology; Salmonella enterica - drug effects; synbiotic; Synbiotics
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu12113259

Certain non-digestible oligosaccharides (NDO) are specifically fermented by bifidobacteria along the human gastrointestinal tract, selectively favoring their growth and the production of health-promoting metabolites. In the present study, the ability of the probiotic strain subsp. CECT7210 (herein referred to as IM-1 ) to utilize a large range of oligosaccharides, or a mixture of oligosaccharides, was investigated. The strain was able to utilize all prebiotics screened. However, galactooligosaccharides (GOS), and GOS-containing mixtures, effectively increased its growth to a higher extent than the other prebiotics. The best synbiotic combination was used to examine the antimicrobial activity against , , and in co-culture experiments. was inhibited by the synbiotic, but it failed to inhibit . Moreover, growth decreased during co-culture with IM-1 . Furthermore, adhesion experiments using the intestinal cell line HT29 showed that the strain IM-1 was able to displace some pathogens from the enterocyte layer, especially and , and prevented the adhesion of and . In conclusion, a new synbiotic (probiotic strain IM-1 and GOS) appears to be a potential effective supplement for maintaining infant health. However, further studies are needed to go more deeply into the mechanisms that allow IM-1 to compete with enteropathogens.